Similar articles

• Angiotensin-converting enzyme inhibitor or Angiotensin receptor blocker use and renal outcomes-reply.

  Hsu CC, Liu JS, Tarng DC. Hsu CC, et al. JAMA Intern Med. 2014 Oct;174(10):1706-7. doi: 10.1001/jamainternmed.2014.1578. JAMA Intern Med. 2014. PMID: 25285739 No abstract available.
• Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use and renal outcomes: prevalent user designs may overestimate benefit.

  Tomlinson L, Smeeth L. Tomlinson L, et al. JAMA Intern Med. 2014 Oct;174(10):1706. doi: 10.1001/jamainternmed.2014.1585. JAMA Intern Med. 2014. PMID: 25285737 No abstract available.
• Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.

  Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, Hsu CC, Tarng DC. Hsu TW, et al. JAMA Intern Med. 2014 Mar;174(3):347-54. doi: 10.1001/jamainternmed.2013.12700. JAMA Intern Med. 2014. PMID: 24343093
• The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease.

  Leon SJ, Tangri N. Leon SJ, et al. Can J Cardiol. 2019 Sep;35(9):1220-1227. doi: 10.1016/j.cjca.2019.06.029. Epub 2019 Jul 11. Can J Cardiol. 2019. PMID: 31472818 Review.
• Arterial hypertension and proteinuria in pediatric chronic kidney disease.

  Simonetti GD, Bucher BS, Tschumi S, Lava SA, Bianchetti MG. Simonetti GD, et al. Minerva Pediatr. 2012 Apr;64(2):171-82. Minerva Pediatr. 2012. PMID: 22495191 Review.